

pFUSE-SEAP-rFc

Plasmid designed for the expression of a SEAP-Fc Fusion protein

Catalog # pfuse-rsp

For research use only

Version 20K04-MM

PRODUCT INFORMATION

Content:

- 20 µg of pFUSE-SEAP-rFc plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.
- Expression of SEAP-rFc was confirmed by using QUANTI-Blue™ Solution
- SEAP-rFc protein was purified using protein G affinity chromatography.

GENERAL PRODUCT USE

pFUSE-SEAP-Fc plasmids express a SEAP-Fc fusion protein generated by fusing the gene encoding for human secreted alkaline phosphatase (SEAP) and the Fc region of an immunoglobulin G (IgG).

pFUSE-SEAP-Fc plasmids yield high levels of Fc-Fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, Chinese hamster ovary (CHO) cells, monkey COS cells and human embryonic kidney (HEK)293 cells. These cells are commonly used in protein purification systems.

SEAP-Fc fusion proteins are secreted and can be easily detected in the supernatant of pFUSE-SEAP-Fc-transfected cells by using QUANTI-Blue™ Solution, a SEAP detection medium. SEAP-Fc fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

PLASMID FEATURES

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **SEAP-rFc** was generated by fusing the gene encoding for human SEAP with the Fc region of rabbit IgG. This region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the SEAP and Fc moieties, allowing each part of the molecule to function independently.
- **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.
- **ori:** A minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

1. Kim DW *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *91(2):217-23*.

2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol.* 8(1):466-72.

3. Carswell S. & Alwine J.C. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol.* 9(10):4248-58.

4. Yu J. & Russell J.E. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage


This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
Agar Protein G/ Agarose QUANTI-Blue™ Solution	gel-agg-2 rep-qbs

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com



NotI (-1)
1 GCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACATAACGCTCTCCATCAAACAAAACGAAACA

PvuII (172)
SgfI (171)
101 AAACAACTAGCAAAATAGGCTGTCCCAAGTGCAGGTGCCAGAACATTTCTCTATCGAAGGATCTGCGATCGCTCCGGTGCCCGTCACTGGGCA

201 GAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTGCGCAATTGAACGGGTGCTAGAGAAGTGGCGGGGTAAGTGGGAAAGTGTG

Psp1406I (368)
301 TCGTGTACTGGCTCCGCTTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCGGTGAACGTTCTTTTTTCGCAACGGGTTTCCCGCCAG

HindIII (410) **Bsu36I (456)**
401 AACACAGCTGAAGCTTCGAGGGCTCGCATCTCTCTTACGCGCCCGCCCTACCTGAGGGCCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCT

501 CCGCGCTGTGGTCCCTCTGAACTGCGTCCGCGCTAGGTAAGTTAAAGTCAAGTGCAGACCGGGCCTTTGTCGGCGCTCCCTTGGAGCTACCTA

601 GACTCAGCCGGCTCTCCACGCTTTGCTGACCCTGCTTCAACTCTACGCTTTTGTTCGTTTTCTGTTCTGCCCGTTACAGATCCAAGCTGTGACC

AgeI (717) **BspHI (740)** **SphI (758)** **Bsu36I (786)**
701 GCGCCCTACCTGAGATCACCGTTTCAGCTGAGGAGGCACATCATGATTCTGGGGCCCTGCATGCTGCTGCTGCTGCTGCTGGGCTGAGGCTACAGC

801 TCTCCCTGGGCATCATCCAGTTGAGGAGGAGAACCAGGACTTCTGGAACCGCAGGCGAGCCGAGGCCCTGGGTGCCCAAGAAGCTGCAGCCTGCACA

201 L S L G I I P V E E E N P D F W N R E A A E A L G A A K K L Q P A Q

BamHI (968)
901 GACAGCCGCAAGAACCTCATCTTCTGGGCGATGGGATGGGGGTGCTACGGTGACAGCTGCCAGGATCCTAAAAGGCGAGAAGAAGGACAAACTG

531 T A A K N L I I F L G D G M G V S T V T A A R I L K G Q K K D K L

NdeI (1034)
1001 GGGCCTGAGATACCCCTGGCTATGGACCGCTTCCCATATGTGGCTGTCCAAGACATACAATGTAGACAAACATGTGCCAGACAGTGGAGCCACAGCCA

871 G P E I P L A M D R F P Y V A L S K T Y N V D K H V P D S G A T A

BstXI (1131)
1101 CGGCTACCTGTGCGGGTCAAGGGCAACTTCCAGACCATTGGCTTGTAGTGCAGCCGCGCTTTAACCAGTGAACACGACACGCGGCAACGAGGTCAT

1201 T A Y L C G V K G N F Q T I G L S A A A R F N Q C N T T R G N E V I

BstEII (1245)
1201 CTCCGTGATGAATCGGGCAAGAAAGCAGGGAAGTCACTGGGAGTGGTAACCACCCACACGAGTGCAGCAGCCTCGCCAGCCGGCACCTACGCCACACG

1531 S V M N R A K K A G K S V G V V T T T R V Q H A S P A G T Y A H T

1301 GTGAACCGCAACTGGTACTCGGACCGCAGCTGCTGCTCGGCCCGCAGGAGGGGTGCCAGGACATCGCTACGACGCTCATCTCCAACATGGACATTG

1871 V N R N W Y S D A D V P A S A R Q E G C Q D I A T Q L I S N M D I

1401 ATGTGATCCTGGTGGAGGCCAAAGTACATGTTTCGCATGGGAACCCAGACCTGAGTACCCAGATGACTACAGCAAGGTGGACCAGGCTGGACGG

2201 D V I L G G G R K Y M F R M G T P D P E Y P D D Y S Q G G T R L D G

SacI (1564)
1501 GAAGAATCTGGTGAGGAATGGCTGGCAAGCGCCAGGGTGCCTGGTATGTGGAACCGCACTGAGCTCATGCAAGGCTTCCCTGGACCCGCTGTGACC

2531 K N L V Q E W L A K R Q G A R Y V W N R T E L M Q A S L D P S V T

1601 CATCTCATGGGTCTCTTTGAGCCTGGAGACATGAAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGC

2871 H L M G L F E P G D M K Y E I H R D S T L D P S L M E M T E A A L

SacII (1719) **PshAI (1756)**
1701 GCCTGCTGAGCAGGAACCCCGCGGCTTCTCCTTCTGAGGGTGGTGCATCGACCAGGTCATCACGAAAGCAGGGCTTACCGGCACTGACTGA

3201 R L L S R N P R G F F L F V E G G R I D H G H H E S R A Y R A L T E

1801 GACGATCATGTTGACGAGCCATTGAGAGGGCGGCCAGCTCACGAGGAGGACAGCTGAGCCTGCTACTGCCGACCACTCCACGCTTCTTCC

3531 T I M F D D A I E R A G Q L T S E E D T L S L V T A D H S H V F S

XcmI (1928)
SacI (1923)
1901 TTCGGAGGCTACCCCTGCGAGGGAGTCCATCTTCGGGCTGGCCCTGGCAAGGCCCGGACAGGAAGGCTACACGGTCTCTATACGGAACGGTC

3871 F G G Y P L R G S S I F G L A P G K A R D R K A Y T V L L Y G N G

2001 CAGGCTATGTCTAAGGACGCGCCCGCCGGATGTTACCGAGAGCAGAGCGGGAGCCCGAGTATCGGACGAGTACAGAGTCCCTGGACGAAGA

4201 P G Y V L K D G A R P D V T E S E S G S P E Y R Q Q S A V P L D E E

BssHII (2131)
2101 GACCCACGACGGCGAGGACGTGGCGGTGTTCCGCGCGGCCCGCAGGCGCACCTGTTTACGGCGTGACGAGGACAGACCTTATAGCGACGTCATGGCC

4531 T H A G E D V A V F A R G P Q A H L V H G V Q E Q T F I A H V M A

BstXI (2288)
2201 TTCGCCGCTGCTGGAGCCCTACCCGCTGCGACCTGGCGCCCCCGCGGACACCAGCCGCGCACCCGGGGCGGTCCCGTCCAAGCGTCTGG

4871 F A A C L E P Y T A C D L A P P A G T T D A A H P G R S R S K R L

BglIII (2302) **PmlI (2316)** **BspHI (2387)**
2301 ATAGATCTAGCAAGCCCAAGTCCCAACCCCTGAACTCTGGGGGACCGTGTCTTTCATCTTCCCCCAAAACCAAGGACACCTCATGATCTCAC

11 S K P T C P P P E L L G G P S V F I F P P K P K D T L M I S

5201 D R S S K P T C P P P E L L G G P S V F I F P P K P K D T L M I S

FspI (2486)
2400 GCACCCCGAGGTCACATGCGTGGTGGTGGACGTGAGCCAGGATGACCCCGAGGTGCAAGTTCACATGGTACATAAACAACGAGCAGGTGCGCACGCCCG

311 R T P E V T C V V V D V S Q D D P E V Q F T W Y I N N E Q V R T A R

5531 R T P E V T C V V V D V S Q D D P E V Q F T W Y I N N E Q V R T A R

2500 GCCCGGCTACGGGAGCAGCAGTTCACAGCAGCAGTCCGCGTGGTCAACCCCTCCCATCGCGCACAGGACTGGCTGAGGGGCAAGGAGTTCAAGT

641 P P L R E Q Q F N S T I R V V S T L P I A H Q D W L R G K E F K C

5861 P P L R E Q Q F N S T I R V V S T L P I A H Q D W L R G K E F K C

NcoI (2684)
2599 CAAAGTCCACAACAGGCACTCCCGGCCCATCGAGAAAACCTCTCCAAGCCAGAGGGCAGCCCTGGAGCCGAAGGTCTACACCATGGGCCCTCC

971 K V H N K A L P A P I E K T I S K A R G Q P L E P K V Y T M G P P

6191 K V H N K A L P A P I E K T I S K A R G Q P L E P K V Y T M G P P

